Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

IMPORTANCE Precision oncology using comprehensive genomic profiling (CGP) by next-
generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical …

Treatment options for patients with NRAS-mutant melanoma are limited and lack an efficient
targeted drug combination that significantly increases overall and progression-free survival …

Background MEK inhibitors (MEKi) were shown to be clinically insufficiently effective in
patients suffering from BRAF wild-type (BRAF WT) melanoma, even if the MAPK pathway …

Background A phase 1a first-in-human study evaluated the safety/tolerability, preliminary
antitumour activity and pharmacokinetics of the oral MEK1/2 inhibitor FCN-159 in Chinese …

About 25% of melanoma harbor activating NRAS mutations, which are associated with
aggressive disease therefore requiring a rapid antitumor intervention. However, no efficient …

Anaplastic thyroid carcinoma (ATC) is an aggressive cancer that requirements rapid
diagnosis and multimodal treatment. Next-generation sequencing (NGS) aids in …

Currently, in the absence of BRAFV600 mutation, the management of advanced melanomas
is based on immunotherapies, but only half of the patients are responders. RAF1 (also …

Background Melanomas frequently harbour somatic mutations in BRAF (40%) or NRAS
(20%). Impact of NRAS mutations on the therapeutic outcome of immune checkpoint …

Background Only a fraction of patients with metastatic melanoma derive durable benefit from
approved treatments. The clinical impact of personalized medicine strategies for melanoma …